188 related articles for article (PubMed ID: 6424462)
21. Intravenous immune globulin therapy in hypogammaglobulinemia. A review.
Pirofsky B
Am J Med; 1984 Mar; 76(3A):53-60. PubMed ID: 6424457
[TBL] [Abstract][Full Text] [Related]
22. 1040 prophylactic infusions with an unmodified intravenous immunoglobulin product causing few side-effects in patients with antibody deficiency syndromes.
Björkander J; Wadsworth C; Hanson LA
Infection; 1985; 13(3):102-10. PubMed ID: 4030106
[TBL] [Abstract][Full Text] [Related]
23. Intravenous therapy with gamma globulin.
Dwyer JM
Adv Intern Med; 1987; 32():111-35. PubMed ID: 3548246
[TBL] [Abstract][Full Text] [Related]
24. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa. Treatment with intravenous immune globulin.
Holder IA; Naglich JG
Am J Med; 1984 Mar; 76(3A):161-7. PubMed ID: 6424445
[TBL] [Abstract][Full Text] [Related]
25. Measles antibody trough levels after treatment with immunoglobulin products and predicted levels assuming lower measles antibody specifications.
Vandeberg P; Cruz MC; Griffin R
Transfusion; 2018 Dec; 58 Suppl 3():3072-3077. PubMed ID: 30430616
[TBL] [Abstract][Full Text] [Related]
26. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study.
Gardulf A; Nicolay U; Asensio O; Bernatowska E; Böck A; Carvalho BC; Granert C; Haag S; Hernández D; Kiessling P; Kus J; Pons J; Niehues T; Schmidt S; Schulze I; Borte M
J Clin Immunol; 2006 Mar; 26(2):177-85. PubMed ID: 16758340
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease.
Cunningham-Rundles C; Siegal FP; Smithwick EM; Lion-Boulé A; Cunningham-Rundles S; O'Malley J; Barandun S; Good RA
Ann Intern Med; 1984 Oct; 101(4):435-9. PubMed ID: 6206756
[TBL] [Abstract][Full Text] [Related]
28. Replacement therapy with high dose intravenous gamma-globulin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia.
Roifman CM; Gelfand EW
Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S92-6. PubMed ID: 3399285
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy.
Orange JS; Belohradsky BH; Berger M; Borte M; Hagan J; Jolles S; Wasserman RL; Baggish JS; Saunders R; Grimbacher B
Clin Exp Immunol; 2012 Aug; 169(2):172-81. PubMed ID: 22774992
[TBL] [Abstract][Full Text] [Related]
30. Safety and patient acceptability of intravenous immune globulin in 10% maltose.
Ochs HD; Buckley RH; Pirofsky B; Fischer SH; Rousell RH; Anderson CJ; Wedgwood RJ
Lancet; 1980 Nov; 2(8205):1158-9. PubMed ID: 6107768
[TBL] [Abstract][Full Text] [Related]
31. Complement interaction with immune serum globulin and immune globulin intravenous.
Bing DH
Am J Med; 1984 Mar; 76(3A):19-24. PubMed ID: 6424450
[TBL] [Abstract][Full Text] [Related]
32. Pathogen-specific IgG antibody levels in immunodeficient patients receiving immunoglobulin replacement do not provide additional benefit to therapeutic management over total serum IgG.
Chua I; Lagos M; Charalambous BM; Workman S; Chee R; Grimbacher B
J Allergy Clin Immunol; 2011 Jun; 127(6):1410-1. PubMed ID: 21376379
[No Abstract] [Full Text] [Related]
33. Home treatment of antibody-deficiency syndromes with intravenous immune globulin.
Sorensen RU; Kallick MD; Berger M
J Allergy Clin Immunol; 1987 Dec; 80(6):810-5. PubMed ID: 3693759
[TBL] [Abstract][Full Text] [Related]
34. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection.
National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group
N Engl J Med; 1991 Jul; 325(2):73-80. PubMed ID: 1675763
[TBL] [Abstract][Full Text] [Related]
35. Clinical tolerance and catabolism of plasmin-treated gamma-globulin for intravenous application.
Barandun S; Castel V; Makula MF; Morell A; Plan R; Skvaril F
Vox Sang; 1975; 28(3):157-75. PubMed ID: 47211
[TBL] [Abstract][Full Text] [Related]
36. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency.
Berger M
Immunol Allergy Clin North Am; 2008 May; 28(2):413-37, x. PubMed ID: 18424340
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
[TBL] [Abstract][Full Text] [Related]
38. Intravenous immune globulin therapy. Treatment of a patient with severe immunodeficiency, chronic malabsorption, and fulminant septicemia.
Gonzalez EB; Guernsey BG; Ingrim NB; Ichikawa Y; Daniels JC
Arch Intern Med; 1985 May; 145(5):945-6. PubMed ID: 3922322
[TBL] [Abstract][Full Text] [Related]
39. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies.
Orange JS; Grossman WJ; Navickis RJ; Wilkes MM
Clin Immunol; 2010 Oct; 137(1):21-30. PubMed ID: 20675197
[TBL] [Abstract][Full Text] [Related]
40. Safety and toxicity of a new serum immunoglobulin G intravenous preparation, IGIV pH 4.25.
Pirofsky B
Rev Infect Dis; 1986; 8 Suppl 4():S457-63. PubMed ID: 3092311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
